Accreditation

PROGRAM EVALUATION AND REQUEST FOR CREDIT

Coming soon

TARGET AUDIENCE

Community and academic medical oncologists, hematologists, advanced practitioners (NP/PA, PharmD), and other clinicians who treat patients with CLL

LEARNING OBJECTIVES

After participating in the activity, participants should be better able to

  • Determine how factors such as patient age, performance status, comorbidities, and mutational status impact the choice of therapy for patients with CLL
  • Assess the safety and efficacy of current and emerging agents and regimens for patients with newly diagnosed CLL
  • Evaluate approaches to the treatment of patients with relapsed/refractory CLL, including optimal sequencing of agents

CONTINUING EDUCATION

An application has been made to the UEMS EACCME® for CME accreditation of this event.

DISCLOSURE OF RELATIONSHIPS WITH COMMERCIAL INTERESTS

It is the policy of Bio Ascend, LLC to ensure balance, independence, objectivity, and scientific rigor in all Bio Ascend, LLC events. All individuals planning/developing content are expected to disclose to the learners all relevant financial relationships prior to the beginning of the continuing education (CE) activity. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services influence practice and/or patient recommendations. Bio Ascend, LLC must identify and resolve any potential conflict of interest prior to activity development and disclosure of these relationships will be included in all event materials so that participants may formulate their own judgments in interpreting content and in evaluating recommendations. Failure or refusal to provide disclosure information will prohibit anyone from presenting at/or participating in the planning of this activity.

DISCUSSION OF INVESTIGATIONAL AND OFF-LABEL USAGE

This faculty may discuss unlabeled or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for approved indications, contraindications, and warnings.

DISCLAIMER

Participants have a responsibility to use newly acquired information to improve their practice and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted